IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
Context Glutamine is the main source of energy of the enterocyte and diarrhea and weight loss are frequent in HIV infected patients. Objective To determine the effect of alanyl-glutamine supplementation on intestinal permeability and absorption in these patients. Methods Randomized double-blinde...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
2013-03-01
|
Series: | Arquivos de Gastroenterologia |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032013000100056&lng=en&tlng=en |
id |
doaj-1b9c5f9c96974873aec232d6efef5e99 |
---|---|
record_format |
Article |
spelling |
doaj-1b9c5f9c96974873aec232d6efef5e992020-11-25T02:48:55ZengInstituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)Arquivos de Gastroenterologia1678-42192013-03-01501566310.1590/S0004-28032013000100011S0004-28032013000100056IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trialRoberio Dias LEITENoelia Leal LIMAChristiane Araujo Chaves LEITECalil Kairalla FARHATRichard Littleton GUERRANTAldo Angelo Moreira LIMAContext Glutamine is the main source of energy of the enterocyte and diarrhea and weight loss are frequent in HIV infected patients. Objective To determine the effect of alanyl-glutamine supplementation on intestinal permeability and absorption in these patients. Methods Randomized double-blinded, placebo-controlled study using isonitrogenous doses of alanyl-glutamine (24 g/day) and placebo (glycine, 25 g/day) during 10 days. Before and after this nutritional supplementation lactulose and mannitol urinary excretion were determined by high performance liquid chromatography. Results Forty six patients with HIV/AIDS, 36 of whom were male, with 37.28 ± 3 (mean ± standard error) years were enrolled. Twenty two and 24 subjects were treated with alanyl-glutamine and with glycine respectively. In nine patients among all in the study protocol that reported diarrhea in the 14 days preceding the beginning of the study, mannitol urinary excretion was significantly lower than patients who did not report this symptom [median (range): 10.51 (3.01–19.75) vs. 15.37 (3.93–46.73); P = 0.0281] and lactulose/mannitol ratio was significantly higher [median (range): 0.04 (0.00–2.89) vs. 0.02 (0.00–0.19); P = 0.0317]. There was also a significant increase in mannitol urinary excretion in the group treated with alanyl-glutamine [median (range): 14.38 (8.25–23.98) before vs 21.24 (6.27–32.99) after treatment; n = 14, P = 0.0382]. Conclusion Our results suggest that the integrity and intestinal absorption are more intensely affected in patients with HIV/AIDS who recently have had diarrhea. Additionally, nutritional supplementation with alanyl-glutamine was associated with an improvement in intestinal absorption.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032013000100056&lng=en&tlng=enAbsorcao intestinalGlutaminaHIVPlacebo |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roberio Dias LEITE Noelia Leal LIMA Christiane Araujo Chaves LEITE Calil Kairalla FARHAT Richard Littleton GUERRANT Aldo Angelo Moreira LIMA |
spellingShingle |
Roberio Dias LEITE Noelia Leal LIMA Christiane Araujo Chaves LEITE Calil Kairalla FARHAT Richard Littleton GUERRANT Aldo Angelo Moreira LIMA IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial Arquivos de Gastroenterologia Absorcao intestinal Glutamina HIV Placebo |
author_facet |
Roberio Dias LEITE Noelia Leal LIMA Christiane Araujo Chaves LEITE Calil Kairalla FARHAT Richard Littleton GUERRANT Aldo Angelo Moreira LIMA |
author_sort |
Roberio Dias LEITE |
title |
IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial |
title_short |
IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial |
title_full |
IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial |
title_fullStr |
IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial |
title_full_unstemmed |
IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial |
title_sort |
improvement of intestinal permeability with alanyl-glutamine in hiv patients: a randomized, double blinded, placebo-controlled clinical trial |
publisher |
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) |
series |
Arquivos de Gastroenterologia |
issn |
1678-4219 |
publishDate |
2013-03-01 |
description |
Context Glutamine is the main source of energy of the enterocyte and diarrhea and weight loss are frequent in HIV infected patients. Objective To determine the effect of alanyl-glutamine supplementation on intestinal permeability and absorption in these patients. Methods Randomized double-blinded, placebo-controlled study using isonitrogenous doses of alanyl-glutamine (24 g/day) and placebo (glycine, 25 g/day) during 10 days. Before and after this nutritional supplementation lactulose and mannitol urinary excretion were determined by high performance liquid chromatography. Results Forty six patients with HIV/AIDS, 36 of whom were male, with 37.28 ± 3 (mean ± standard error) years were enrolled. Twenty two and 24 subjects were treated with alanyl-glutamine and with glycine respectively. In nine patients among all in the study protocol that reported diarrhea in the 14 days preceding the beginning of the study, mannitol urinary excretion was significantly lower than patients who did not report this symptom [median (range): 10.51 (3.01–19.75) vs. 15.37 (3.93–46.73); P = 0.0281] and lactulose/mannitol ratio was significantly higher [median (range): 0.04 (0.00–2.89) vs. 0.02 (0.00–0.19); P = 0.0317]. There was also a significant increase in mannitol urinary excretion in the group treated with alanyl-glutamine [median (range): 14.38 (8.25–23.98) before vs 21.24 (6.27–32.99) after treatment; n = 14, P = 0.0382]. Conclusion Our results suggest that the integrity and intestinal absorption are more intensely affected in patients with HIV/AIDS who recently have had diarrhea. Additionally, nutritional supplementation with alanyl-glutamine was associated with an improvement in intestinal absorption. |
topic |
Absorcao intestinal Glutamina HIV Placebo |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032013000100056&lng=en&tlng=en |
work_keys_str_mv |
AT roberiodiasleite improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial AT noelialeallima improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial AT christianearaujochavesleite improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial AT calilkairallafarhat improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial AT richardlittletonguerrant improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial AT aldoangelomoreiralima improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial |
_version_ |
1724745900738215936 |